Interleukin‐2 injected around tumor‐draining lymph nodes in head and neck cancer
- 1 March 1991
- journal article
- clinical trial
- Published by Wiley in Head & Neck
- Vol. 13 (2) , 125-131
- https://doi.org/10.1002/hed.2880130208
Abstract
Twenty patients with recurrent, inoperable head and neck squamous cell carcinoma received perilymphatic injections of natural interleukin‐2 (nlL‐2) for 10 days. Ten patients received 200 units (U) of nlL‐2; five 1,000 U; and five 5,000 U. Irrespective of the location of the recurrence, the injections were always performed 1.5 cm below the insertion of the sternocleidomastoid muscle on the mastoid. When the ipsilateral lymphatic chain was still present, they were performed on the same side as the tumor site, whereas when it had been stripped as a result of previous surgery, they were contralateral. Patients who had undergone bilateral neck dissection were injected on the tumor side. Whenever possible, the treatment was repeated after 45 day intervals. In 13 patients (65%) with bilateral or contralateral lymph nodes, complete or partial disappearance of the lesion was observed. Despite these marked responses, the tumor always relapsed, and subsequent IL‐2 courses were poorly effective. There were no systemic disturbances during or after treatment, but only moderate local swelling and pain.Keywords
This publication has 18 references indexed in Scilit:
- Lymphokine-activated tumor inhibition: Combinatory activity of a synthetic nonapeptide from interleukin-1, interleukin-2, interleukin-4, and interferon-γ injected around tumor-draining lymph nodesInternational Journal of Cancer, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Helper strategy in tumor immunology: Expansion of helper lymphocytes and utilization of helper lymphokines for experimental and clinical immunotherapyCancer and Metastasis Reviews, 1988
- Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.The Journal of Experimental Medicine, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Strategies for cell-mediated immunotherapy of cancer: killing or help?Immunology Today, 1986
- A microcomputer program for probit analysis of interleukin-2 (IL-2) titration dataJournal of Immunological Methods, 1986
- Functional properties in Sézary cells with an unusual phenotypeClinical Immunology and Immunopathology, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982